* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Scranton Heart Institute, PC
Survey
Document related concepts
Electrocardiography wikipedia , lookup
Cardiovascular disease wikipedia , lookup
Saturated fat and cardiovascular disease wikipedia , lookup
Baker Heart and Diabetes Institute wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Jatene procedure wikipedia , lookup
Remote ischemic conditioning wikipedia , lookup
Coronary artery disease wikipedia , lookup
Quantium Medical Cardiac Output wikipedia , lookup
History of invasive and interventional cardiology wikipedia , lookup
Transcript
Anti-Platelet Medications For Elective Percutaneous Coronary Interventional Procedures - 2011 Stafford M. Smith, M.D., FACP, FACC Scranton Heart Institute, P.C. Blood Platelets – High Power Magnification Dense (delta) granules contain ADP, Ca++, and serotonin. Lambda granules contain hydrolytic enzymes. Alpha granules contain PF4, transforming GFβ1, platelet-derived growth factor, fibronectin, B-thromboglobulin, vWF, fibrinogen, and Factors V and XII. Scranton Heart Institute, P.C. Thienopyridine Agents Ticlopidine: ~ 30-35% platelet inhibition *2% incidence of serious neutropenia. Clopidogrel: ~ 30-50% platelet inhibition. Prasugrel: ~ 60% platelet inhibition TRITON-TIMI 38 – 50% reduction in stent thrombosis (ST) was offset by increased bleeding (particularly in high risk groups). Ticagrelor: ~ 70% platelet inhibition (shortacting, reversible agent) PLATO – Significant reduction in ischemic events without an increase in bleeding. Scranton Heart Institute, P.C. CLOPIDOGREL IS INDICATED FOR: 1. A reduction of rate of CV death, MI, stroke, or refractory ischemia in patients with ACS (unstable angina or non-ST-elevation MI), including those who are managed medically and those with coronary revascularization. 2. To reduce the rate of death from any cause, reinfarction, or stroke in patients with STEMI. 3. To reduce the rate of new ischemic stroke or MI, and other vascular deaths in patients with history of recent MI, STROKE, or PAD. Scranton Heart Institute, P.C. Clopidogrel – “Boxed Warning” Effectiveness is dependent on activation to an active metabolite via CYP2C19. Poor metabolizers of CYP2C19 treated with clopidogrel at recommended doses exhibit higher cardiovascular (CV) event rates following acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention than patients with normal CYP2C19 function. Tests are available to identify a patient's CYP2C19 genotype and to determine therapeutic strategy. Consider alternative treatment in poor metabolizers. Scranton Heart Institute, P.C. PRASUGREL INDICATIONS A reduction of thrombotic CV events [stent thrombosis (ST)] in patients with acute coronary syndrome (ACS) [unstable angina, non-ST-elevation MI] and STEMI, who are to be managed with percutaneous coronary intervention (PCI). Scranton Heart Institute, P.C. Prasugel’s “boxed warning” 1. 2. 3. 4. 5. 6. 7. 8. Prasugrel may cause significant, sometimes fatal, bleeding. Risk factors include: <60kg body weight, propensity to bleed, and concomitant use of medications that may increase bleeding. Do not use in patients with active pathological bleeding or history of transient ischemic attacks (TIA) or stroke. Prasugrel is not recommended in patients ≥75 yrs., due to increased risk of fatal intracranial bleeding. Do not start prasugrel in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). Discontinue prasugrel at least 7 days prior to surgery. Suspect bleeding in any patient who is hypotensive that has recently undergone coronary angiography, PCI, CABG, or other surgical procedures. If possible, manage bleeding without discontinuation. Discontinuation of prasugrel within the first few weeks after an ACS increases the risk of subsequent cardiovascular events. Scranton Heart Institute, P.C. Coronary Heart Disease Syndromes And Interventional Procedures 1.6 million hospital discharges for ACS in the U.S. in 2003. Roughly 30% of ACS patients have STEMI. ~ 2.7 million heart catheterizations are done in the US annually. ~ 1/3 of these require coronary intervention (~900,000/year). The majority of interventional procedures involve the use of endovascular stents. Approximately 1 million coronary stents are implanted in the US annually (~ 1.3 stents per patient) Scranton Heart Institute, P.C. Dual Anti-Platelet Therapy (DAPT) 1 Randomized Trial And Several Registries Suggesting A Benefit With Prolonged Use Of DAPT CURE: 22% reduction in adverse clinical events with DAPT (31% reduction in patients that underwent PCI with stents) Only BMS were used in this study. The Bern-Rotterdam Experience: 65% of stent thromboses (ST) occurred within the first 6 months after PCI and DES. The annual rate of ST according to this registry was 0.6% out to 4 years. Duke Database: Increased incidence of death or MI in DES patients if DAPT was discontinued within 6 months. The Tycoon Registry: 4 late ST when DAPT was discontinued after 1 year (with DES). None ST if DAPT continued out to 2 years. Scranton Heart Institute, P.C. Dual Anti-Platelet Therapy (DAPT) Conflicting Data Regarding The Use Of Prolonged DAPT The Guthrie Registry: No increase in CV events for DES patients if DAPT discontinued after 1 year. The Milan Database: No difference in events for DES patients if DAPT was discontinued after 6 months. The large DAPT trial will definitively address the optimal length of DAPT Rx. Results will be available in 2015. Scranton Heart Institute, P.C. MECHANISMS OF PLATELET ACTIVATION AND AGGREGATION. Chhatriwalla A K , Bhatt D L Circ Cardiovasc Interv 2008;1:217-225 Copyright © American Heart Association Scranton Heart Institute, P.C. PLATELET AGGREGATION Platelets aggregate by using fibrinogen and vWF as a connecting bridge. The glycoprotein IIbIIIa receptor binds fibrinogen, fibronectin, vitronectin, thrombospondin, and vWF. Scranton Heart Institute, P.C. AHA/ACC/SCAI/ACS/ADA SCIENCE ADVISORY Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents A Science Advisory From the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians J Am Coll Cardiol, 2007; 49:734-739, doi:10.1016/j.jacc.2007.01.003 (Published online 17 January 2007). © 2007 by the American College of Cardiology Foundation This advisory stresses the importance of 12 months of dual antiplatelet therapy after placement of a drug-eluting stent, and educating the patient and healthcare providers about hazards of premature discontinuation. It also recommends postponing elective surgery for 1 year, and if surgery cannot be deferred, considering the continuation of aspirin during the perioperative period in highrisk patients with drug-eluting stents. Scranton Heart Institute, P.C. ACC/AHA Guidelines J Am Coll Cardiol, 2009; 54:2205-2241, doi:10.1016/j.jacc.2009.10.015 (Published online 18 November 2009). © 2009 by the American College of Cardiology Foundation 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines A loading dose of thienopyridine is recommended for patients in whom PCI is planned…(as early as possible) before or at the time of PCI. [Class 1] In patients receiving a stent: The duration of thienopyridine therapy should be at least 12 months. [Class 1] If the risk of morbidity due to bleeding outweighs the benefit, earlier discontinuation should be considered. [Class 1] Continuation of clopidogrel or prasugrel beyond 15 months may be considered in patients undergoing DES placement. [Class 2B] Scranton Heart Institute, P.C. Prevalence, Predictors, and Long-Term Prognosis of Premature Discontinuation of Oral Antiplatelet Therapy After Drug Eluting Stent Implantation Rossini, Capodanno, Lettieri, Musumeci, et al., Am J Cardiol Vol. 107, 2, P186-19415, Jan 2011 1,358 Consecutive Patients Followed For 3 Years Early Discontinuation (< 12 Months vs. Late Discontinuation (> 12 Months) 52% Increase In Cardiac Events (p < 0.001) 55% Increase in ST (p = 0.038) 65% Increase in All-Cause Mortality (p < 0.001) 76% Increase in Cardiovascular Death (p = 0.007) Scranton Heart Institute, P.C. Duration of Dual Anti-Platelet Therapy After Implantation of Drug-Eluting Stents Park SJ, Park DW, Kim YH, et al. N Engl J Med 2010; Mar 15 Cumulative risk of a cardiac death or MI at 2 years: 1.8% on DAPT, 1.2% on aspirin alone (p = 0.17). No difference in the risk of MI, stroke, stent thrombosis, need for repeat revascularization, major bleeding, or death from any cause. This study had inadequate statistical power to provide a definitive conclusion regarding the safety of clopidogrel discontinuation after 12 months. Additional studies addressing the use of dual antiplatelet therapy after implantation of DES are ongoing. Scranton Heart Institute, P.C. CONCERNS REGARDING PROLONGED DAPT Bleeding: 1% risk of a major bleeding event per year. Cost: (Should improve when generic clopidogrel becomes available ~ 2011?) Perioperative Management: Multiple issues, Hypercoagulability Scranton Heart Institute, P.C. STENT THROMBOSIS Scranton Heart Institute, P.C. Blood Clotting Red Blood Cell Platelet Fibrin Mesh Scranton Heart Institute, P.C. Coronary Stent Thrombosis and Noncardiac Surgery Time Period Patients, n 1996–1998 40 DES, % 0 Time From Mortality PCI to Rate,* % (95% Surgery CI) <42 d 21.4 (10.2– 35.0) <60 d 3.4 (1.2–6.3) Authors Kaluza et al Year 2000 Type Retr, NR Wilson et al 2003 Retr, NR 1990–2000 207 0 Sharma et al 2004 Retr, NR 1995–2000 47 0 <90 d 18.4 (8.6–30.4) Reddy et al 2005 Retr, NR 1999–2004 56 0 ... 8.6 (2.3–17.5) Leibowitz et al 2006 Retr, NR 1995–2002 94 0 <90 d 14.6 (8.1–22.4) Vicenzi et al 2006 Prosp, NR 2001–2004 103 ... <1 y 5.7 (1.8–11.1) Compton et al 2006 Retr, NR 2003–2006 38 100 ... 2.5 (0.0–7.9) Schouten et al 2007 Retr, NR 1999–2005 192 52 <2 y 3.1 (1.0–6.1) PCI indicates percutaneous coronary intervention; Retr, retrospective; Prosp, prospective; and NR, nonrandomized. *Mortality rates were calculated using the adjusted Wald interval. Scranton Heart Institute, P.C. Predictors of DES Thrombosis: Considerations for Prolonged Dual Antiplatelet Therapy (DAPT) Clinical Angiographic Advanced age Acute coronary syndrome Diabetes Low ejection fraction Prior brachytherapy Renal failure Long stents Multiple lesions Overlapping stents Ostial or bifurcation lesions Small vessels Suboptimal stent results Scranton Heart Institute, P.C. CLINICAL ALERT ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning“; A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J Am Coll Cardiol, 2010; 56:321-341, doi:10.1016/j.jacc.2010.05.013 (Published online 28 June 2010). © 2010 by the American College of Cardiology Foundation CYP2C19 polymorphism accounts for only 12% of variability in clopidogrel platelet response. The positive predictive value of CYP2C19 polymorphisms is estimated to be between 12% and 20% in patients with ACS undergoing PCI. Scranton Heart Institute, P.C. Platelet Testing Genetic Testing: CYP2C19 – “Poor Metabolizers” Platelet Function Testing: (“Verify Now”, TEG, others) – “Hyporesponders” [< 20% platelet inhibition] *A positive association with an increased risk of death, MI, and ST Both? Neither? Scranton Heart Institute, P.C. Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction Results From the French Registry of Acute ST-Elevation and Non–ST-Elevation Myocardial Infarction (FAST-MI) Registry Circulation. 2011;123:474-482 January 24, 2011, doi: 10.1161/CIRCULATIONAHA.110.965640 PPI use was not associated with an increased risk for in-hospital events (survival, reinfarction, stroke, bleeding, and transfusion). PPI treatment was not an independent predictor of 1-year survival (hazard ratio, 0.97; 95% confidence interval 0.87 to 1.08; P=0.57) or 1-year MI. PPI use was not associated with an increased risk of cardiovascular events or mortality in patients administered clopidogrel for recent MI, whatever the CYP2C19 genotype. Scranton Heart Institute, P.C. ADDITIONAL CLINICAL TRIALS SUPPORTING THE SAFETY OF CLOPIDOGREL USE WITH PPIs 1. COGENT: 2009 (> 3,600 patients) 2. Sub-analysis from TRITON-TIMI 38: 2009 (> 13,000 patients) 3. Sub-analysis from PRINCIPLE-TIMI 44; 2007 (201 patients) Scranton Heart Institute, P.C. GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) & ESOPHAGEAL CARCINOMA A consideration to support the more liberal use of proton pump inhibitors in the general population… o GERD occurs in 30-40% of adults. o Barrett’s esophagitis affects 1.6% of the general population. o The incidence of esophageal cancer has quadrupled in the past several years (There were >16,000 new cases annually in the US, and > 14,000 deaths recorded annually in the US; as of 2009). o H2 antagonists are less effective than PPIs to control reflux symptoms. Scranton Heart Institute, P.C. Atrial Fibrillation AF: The most common sustained cardiac arrhythmia. The incidence and prevalence of AF increases progressively with age. New cases range from < 0.5% at age 55 to 3.5% at age > 85 years. AF occurs at a frequency of 5% in patients with new ischemic stroke. AF occurs at a frequency of 10% in patients after acute MI. The prevalence of AF in the general population is 0.5 – 1%. Rotterdam Study: The lifetime risk of developing AF at age 55 is ~ 24% in men and 22% in women. Scranton Heart Institute, P.C. Anticoagulation (Anti-Thombin Therapy) in Atrial Fibrillation Requirement Indicated By CHADS2 Score. “Age-Adjusted” Risk Of Stroke Is 4 X – 5 X Increased Without Treatment. Anticoagulation Reduces The Risk To Close To That Of The General Population. Warfarin: Antagonizes Vitamin K-Dependent Clotting Factors (II, VII, IX, X), long T1/2; requires monitoring and dose adjustments. Dabigatran: Reversible Direct Thrombin Inhibitor. Factor X Inhibitors Scranton Heart Institute, P.C. Combination therapy with aspirin, clopidogrel, and warfarin following coronary stenting is associated with a significant risk of bleeding Khurram Z, Chou E, Minutello R, Bergman G, Parikh M, Naidu S, Wong SC, Hong MK. Lenox Hill Hospital, New York, New York, USA. • Patients on chronic warfarin therapy who receive a coronary stent need to be treated with “triple therapy” (aspirin, clopidogrel & warfarin). • Single center study (107 consecutive patients). “Triple therapy” patients were younger and more likely to have hypertension. • “Triple therapy” patients had more major bleeding (6.6% vs. 0%; p = 0.03) and minor bleeding (14.9% vs. 3.8%; p = 0.01), compared with the DAPT group. • In the “triple therapy” group, the INR or aspirin dosage did not influence the bleeding risk. • For patients on warfarin, the addition of DAPT is associated with approximately a 7% major bleeding risk. Scranton Heart Institute, P.C. OCT Image IVUS Image OPTICAL COHERENCE TOMOGRAPHY (OCT) Scranton Heart Institute, P.C. Conclusions DAPT remains the standard of care after coronary stenting (to reduce the incidence of adverse cardiac events (particularly ST). Early discontinuation of DAPT is associated with an increased incidence of serious adverse outcomes. The current recommended minimum duration of DAPT is 12 months after DES. There is concern regarding the previously reported incidence of VLST. Additional studies are ongoing. Scranton Heart Institute, P.C. Clinicians need to weigh the specific risks of surgery vs. the risks of DAPT discontinuation. The incidence of ST associated with specific non-cardiac procedures has not been established. Certain clinical and angiographic features may help identify individuals who may be at an augmented risk of ST. The “boxed warning” identified differences in clopidogrel metabolism, but this phenomenon does not fully explain the differences in clinical events, and the incidence of low anti-platelet activity. Conclusions The role of platelet testing has not been defined. Current testing methods have not correlated well with the liklihood of clinical events. Data regarding the interaction between PPIs and clopidogrel has been mixed. The preponderance of information from randomized trials suggest that there is no significant increase in the incidence of clinical events with this combination. GERD is a common clinical problem, with symptoms similar to IHD, and with serious consequences (left untreated). Scranton Heart Institute, P.C. There is significant overlap in the patient population that require both DAPT and antithrombin Rx. The combination of these agents places the patient at an increased risk of a bleeding event. New antiplatelet and antithrombin agents may prove safer in combination for these indications. Clinical trials are ongoing to address the optimal regimens and durations to be used. New technological devices for interventional cardiologists appear promising to assess and improve the safety of terminating DAPT early.